# Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis

> **NCT02888704** · PHASE1 · COMPLETED · sponsor: **EHL Bio Co., Ltd.** · enrollment: 13 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** ADSTEM Inj. (Adult human mesenchymal stem cells)

## Key facts

- **NCT ID:** NCT02888704
- **Lead sponsor:** EHL Bio Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2017-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02888704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02888704, "Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02888704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*